BioLife Solutions/$BLFS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About BioLife Solutions

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Ticker

$BLFS
Primary listing

Industry

Life Sciences Tools & Services

Employees

159

ISIN

US09062W2044

BLFS Metrics

BasicAdvanced
$1B
-
-$0.23
1.82
-

What the Analysts think about BLFS

Analyst ratings (Buy, Hold, Sell) for BioLife Solutions stock.

Bulls say / Bears say

BioLife Solutions reported a positive earnings surprise in Q1 2025, with earnings per share of $0.04, surpassing analyst expectations of -$0.05, indicating improved financial performance. (Nasdaq)
The company appointed Tony J. Hunt, Executive Chairman of Repligen, to its Board of Directors, bringing extensive bioprocessing experience that could enhance strategic initiatives. (StockTitan)
Analysts have set a consensus price target of $31.17 for BioLife Solutions, suggesting potential upside from the current trading price. (American Banking and Market News)
Insider selling activity has been notable, with executives like EVP Aby J. Mathew selling significant shares, which may raise concerns about internal confidence. (Nasdaq)
The company reported a net loss from continuing operations in Q3 2024, indicating ongoing profitability challenges. (PRNewswire)
BioLife Solutions has a negative net profit margin of -5.57%, reflecting operational inefficiencies that could impact future profitability. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

BLFS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BLFS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BLFS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs